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A novel coronavirus named COVID-19 has begun to spread in Wuhan, China from December 2019 and become a global health concern.[@bib0001] Individuals with underlying diseases are at greater risk and more prone to be critically ill in case of infection so that mortality rate is 49% in subjects entering intensive care units.[@bib0002] It has been reported that critically ill COVID-19 patients remarkably have elevated levels of pro-inflammatory cytokines including IL-6, G-CSF, IP10, MCP1, MIP1A, and TNFα, contributing to outbreak of cytokine storm.[@bib0003] These turn of events lead to acute respiratory distress syndrome and ultimately maybe death[@bib0002] and glucocorticoids were not efficient in reducing rate of mortality.[@bib0004]

It has been suggested that mesenchymal stem cell (MSC) transplantation could be considered as a beneficial approach in treatment many disease. MSC exerts its positive impacts through immunomodulation and differentiation stimulation.[@bib0005] It has proposed that pathogen molecules such as double-stranded RNA in virus is able to increase induction of toll-like receptors (TLRs) on MSC resulting in manifestation of immunomodulatory effects of MSC.[@bib0006] Darwish et al. demonstrated that MSC is potentially able to treat H5N1 infection which has a cytokine profile similar to COVID-19.[@bib0007] The mechanisms of action of MSC on COVID-19 treatment schematically are shown on [Fig. 1](#fig0001){ref-type="fig"} .Fig. 1Mechanims of action MSC therapy on inflammatory process. COVID-19 cause a remarkable increase in pro-inflammatory and inflammatory biomarkers through unknown mechanisms which lead to a critical situation named "cytokine storm" and known as main cause of acute respiratory distress syndrome (ARDS) and multiple organ failure (MOF). Mesenchymal stem cells (MSCs), as a new approach in COVID-19 treatment, convert to anti-inflammatory MSC (MSC2) due to the increase in levels of inflammatory factors such as interferon γ (IFN γ), TNF-α and Interleukin*-*1β (IL-1β). MSC2 suppress proliferation of T cells and give assistance to developing Treg cells by increase in secretion of soluble factors such as transforming growth factor beta (TGF-β), hepatocyte growth factor (HGF), Indoleamine 2,3-dioxygenase (IDO), nitric oxide (NO), prostaglandin E~2~ (PGE~2~), and hemoxygenase (HO). The secreted IDO and PGE~2~ from MSC2 result in conversion of monocytes into macrophages M2 cells which produce anti-inflammatory cytokines such as Interleukin-10 (IL-10) and CC chemokine ligand 18 (CCL18). In addition to indirect impact of COVID-19 in production of MSC2 through inflammatory pathway, it also induces production of soluble factors from MSC2 through direct stimulation of toll-like receptor 3 (TLR3) in MSC2 membrane by its double stranded RNA (dsRNA). All of these processes lead to alleviation in the intensity of cytokine storm and therefore interruption in progress of ARDS and MOF. (Question mark (?): unknown mechanism; Upside arrow: Increase; Down side arrow: Decrease) (Figure is created at biorender.com)Fig 1

Therefore, MSC therapy potentially could be considered as an efficacious and safe treatment approach in COVID-19-induced pneumonia. In this regard, Leng et al. recently demonstrated that with perfusion of 1 × 10^6^ cells per kilogram of weight, almost all the clinical symptoms such as fever, breath shortness, and low oxygen saturation disappeared and the inflammation levels were relieved 2-4 days after MSC transplantation.[@bib0008] Moreover, in a critically ill 65 years old woman, MSC transplantation with 5 × 10^7^ cells three times resulted in significant decrease in CRP and increase in CD3+, CD4+ and CD8+ T cells to the normal ranges. Also, CT images implied to remarkable relieve in pneumonia.[@bib0009] Furthermore, there are 30 registered studies investigating MSC therapy on COVID-19 to explore whether MSC transplantation could be able to shed the light in COVID-19 treatment. A summary of characteristics of registered studies are presented in [Table 1](#tbl0001){ref-type="table"} .Table 1Characteristics of registered studies investigating the effect of stem cell therapy on COVID-19 outcomes.Table 1Applicant and registry numberStudy designCountryDiseaseSample sizeAge (year)DurationInterventionOutcomes1Cao Yang\
ChiCTR2000029580RCTChinaCOVID-19 with severe pneumonia7018-75NRG1: Ruxolitinib + MSC\
G2: SCTSafety, efficacy, improvement rates at 7-days and 1-month, pulmonary function, long-term disability rates and quality of life2Huang Guoxin\
ChiCTR2000029569RCTChinaSevere and critical type of COVID-1930≥18NRG1: SCT\
G2: MSC + SCTPSI, arterial blood gas analysis, mortality, hospitalization day3Charlie Xiang\
ChiCTR2000029606RCTChinaCOVID-19 pneumonia631-99NR (IV infusion)G1: MSC + SCT\
G2: SCT\
G3: SCT + Artificial liver therapy\
G4: SCT + MSC + Artificial liver therapy\
G5: SCTMortality, improvement rate, incidence of shock and multiple organ failure, days in hospital and ICU, ventilation modes and parameters4Fu-Sheng Wang\
*NCT04252118*Non-RCTChinaCOVID-19 pneumonia4018-70180 days\
(IV infusion at Day 0, Day 3, Day 6)G1: MSC + SCT\
G2: SCTSize of chest lesion by CT, side effects, 28 day mortality rate, CD4+ and CD8+ T cell, CRP, ALT, Creatine kinase5Ouyang Qi\
ChiCTR2000030866Non-RCTChinaCOVID-19 (without severe type)30≥1828 days (IV infusion at Day 0, Day 3, Day 6)G1: MSC + SCTOxygenation index, mortality, total T cells, CD4 + T cells, CD8 + T cells, B cells, NK cells, IL-1β, IL-2, IL-6, IL-10, TNF-α, APACHE II score, D-dimer, CRP, procalcitonin6ZhiYong Peng\
*NCT04269525*Non-RCTChinaCOVID-19 pneumonia1018-7528 days (IV infusion at Day 1, Day 3, Day 5, Day 7)G1: Umbilical Cord-Derived MSCOxygenation index, 28 day mortality, hospital stay, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, γ-IFN7Yongxiang Yi\
ChiCTR2000030300Non-RCTChinaCOVID-19 pneumonia918-75NRG1: MSCTime and rate of coronavirus become negative8Tianhe Stem Cell Biotech, Inc.\
*NCT04299152*RCTUSACOVID-19 pneumonia2018-604 weeksG1: MSC\
G2: SCTFeasibility, activated T cells, Th17, chest CT scan9Fu-Sheng Wang\
*NCT04288102*RCTChinaCOVID-19 pneumonia6018-7028 days\
(IV infusion at Day 0, Day 3, Day 6)G1: SCT + MSC\
G2: SCT + placeboImprovement in CTI, side effects of the MSC, all-cause mortality, duration of oxygen therapy and hospitalization10Ruijin Hospital\
*NCT04276987*A Pilot Clinical TrialChinaCOVID-19 with severe pneumonia3018-7528 days (aerosol inhalation at Day 1, Day 2, Day 3, Day 4, Day 5)G1: aerosol inhalation of MSCs-derived exosomesAdverse reaction, TTIC, duration of mechanical ventilation and ICU monitoring, rate of mortality, CRP, pro-BNP, IL-1β, IL-6, IL-8, IL-2R11Robert Chunhua Zhao\
\
ChiCTR2000029990RCTChinaCOVID-19 with Pneumonia(moderate to severe)12018-95NRG1: MSC\
G2: placebo (saline)blood oxygen saturation, recovery time12CAR-T Biotechnology Co., Ltd.\
*NCT04302519*A Pilot Clinical TrialChinaCOVID-19 pneumonia2418-7514 days (IV infusion at Day 1, Day 3, Day 7)G1: MSCDisappear time of ground-glass shadow in the lungs, changes of blood oxygen13Yang Jin\
*NCT04273646*RCTChinaCOVID-19 with severe pneumonia4818-6512 weeks (IV infusion at Day 1, Day 3, Day 5, Day 7)G1: SCT + MSC\
G2: SCT + placeboPneumonia severity index, oxygenation index, side effects, 28 day mortality rate, CRP, procalcitonin, CD3+, CD4+ and CD8+ T cell, lymphocyte count14Jianjun Li\
ChiCTR2000030484RCTChinaCOVID-19 pneumonia9018-70NR (IV infusion at Day 1,\
Day 7)G1: MSC\
G2: MSC + exosomes\
G3: placeboPaO2 / FiO2 or respiratory rate, number of chest lesion by CT, time for cough and dyspnea to become mild or absent, CRP, PCT, SAA15Li Weilin\
ChiCTR2000030173RCTChinaCOVID-19 pneumonia6018-60NRG1: MSC\
G2: SCTpulmonary function, pulmonary CT, chest radiography, nucleic acid test16Jian Bo\
ChiCTR2000030138RCTChinaCOVID-19 pneumonia6016-75NR (IV infusion)G1: MSC\
G2: SCT + placeboClinical index17Liu Yu\
ChiCTR2000030116RCTChinaCOVID-19 with severe pneumonia1618-7528 daysG1: MSC\
G2: MSC in different dose28 day mortality rate, incidence of long-term complications, serum inflammatory cytokines18Ningkun Zhang\
ChiCTR2000030088RCTChinaCOVID-19 with severe pneumonia4018-80NR (IV infusion)G1: MSC\
G2: normal salinenucleic acid of COVID-19, CT scan of ground glass shadow disappeared19Liu Sha\
ChiCTR2000030020Non- RCTChinaCOVID-19 pneumonia2018-70NR (4 times IV infusion)G1: MSCFEV1, lymphocyte subpopulation changes, symptoms improved, inflammation20Stem Cells Arabia\
NCT04313322Non- RCTJordanCOVID-19 pneumonia5≥188 weeks (IV infusion)G1: MSCImprovement of clinical symptoms, Side effects, Real-Time Polymerase Chain Reaction21Ye Qingsong\
*NCT04336254*RCTChinaCOVID-19 with severe pneumonia2018-6528 days (IV infusion at Day 1, Day 4, Day 7)G1: SCT + MSC\
G2: SCT + normal salineTTCI, Lung lesion, IL-1β, IL- 2, TNF-a, ITN-γ, IL- 4, IL- 6, IL- 10, Immunoglobulins, Lymphocyte counts, CRP22Azidus Brasil\
*NCT04315987*Non- RCTBrazilCOVID-19 with severe pneumonia66≥1828 days (IV infusion at Day 1, Day 3, Day 7)G1: SCT + MSC\
Disappearance of ground-glass shadow in lung, 28 day mortality rate, CD4+ and CD8+, blood oxygen23Qi Zhou\
*NCT04331613*Non- RCTChinaCOVID-19 with severe pneumonia9≥1828 days (IV infusion)G1: 3\
G2: 5\
G3: 10 million cell/kgAdverse reactions, Time to SARS-CoV-2, Improvement of clinical symptoms, Lymphocyte count, CRP, ALT, IL-1beta, IL-2, IL-6, IL-824Assistance Publique\
*NCT04333368*RCTFranceCOVID-19 with severe pneumonia60≥1828 days (IV infusion at Day 1, Day 3, Day 5)G1: MSC G2: placeboPaO2/FiO2 ratio, oxygenation index, mortality, IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang225Qingsong Ye\
ChiCTR2000031319RCTChinaCOVID-19 pneumonia2018-65NR (IV infusion)G1: SCT + MSC\
G2: SCT + placeboTTCI, Immune biomarkers, Improvement of clinical symptoms,26Lei Shi\
ChiCTR2000031430Non- RCTChinaCOVID-19 pneumonia20018-80NR (IV infusion at Day 0, Day 3, Day 6)G1: SCT + MSC\
G2: SCTElectrocardiogram, chest CT, Blood gas analysis, blood routine, Liver and kidney function, cytokine analysis, immunoglobulins, CRP, D-Dimer27Leng Nannan\
ChiCTR2000031494Non- RCTChinaCOVID-19 with severe pneumonia3618-90NR (IV infusion)G1: SCT + MSC\
G2: SCTChest imaging, lung function28Nader Tavakoli\
IRCT20140528017891N8RCTIranCOVID-19 pneumonia1018-9528 days (IV infusion at Day 1, Day 3, Day 6)G1: SCT + MSC\
G2: SCT + placeboDeath, pneumonia severity index, oxygen index, CRP, procalcitonin, lymphocyte count, CD3 +, CD4 + and CD8 +, chest CT29Hassan Abolghasemi\
IRCT20200325046860N2Non- RCTIranCOVID-19 pneumonia1018-7028 days (IV infusion at Day 1, Day 3, Day 6)G1: SCT + MSCmortality rate; duration of hospital stay, chest CT30Abbas Pardakhty\
IRCT20140911019125N6Non- RCTIranCOVID-19 pneumonia1018-9528 days (IV infusion at Day 1)G1: SCT + MSCPulmonary condition, Lymphocytes count, clinical signs[^1][^2]Source: <http://www.chictr.org.cn>, <https://clinicaltrials.gov>, <https://www.irct.ir>.
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[^1]: All the registered studies are conducted on both genders

[^2]: MSC: mesenchymal stem cells; SCT: supportive and conventional treatment; NR: not reported; RCT: randomized controlled trial; IV: intravenous; CT: computed tomography; G: group; CTI: critical treatment index; TTCI: time to clinical improvement; pro-BNP: pro-type B natriuretic peptide; ALT: alanine aminotransferase.
